186 related articles for article (PubMed ID: 26918049)
1. Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.
Engelke LH; Hamacher A; Proksch P; Kassack MU
J Cancer; 2016; 7(4):353-63. PubMed ID: 26918049
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines.
Baribeau S; Chaudhry P; Parent S; Asselin É
PLoS One; 2014; 9(1):e86987. PubMed ID: 24466305
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy.
Synowiec A; Brodaczewska K; Wcisło G; Majewska A; Borkowska A; Filipiak-Duliban A; Gawrylak A; Wilkus K; Piwocka K; Kominek A; Waś H; Lewicki S; Siewiera J; Szczylik C; Szenajch J; Kubiak JZ; Kieda C
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982788
[TBL] [Abstract][Full Text] [Related]
4. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
7. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
9. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis.
Qin Y; Li W; Long Y; Zhan Z
Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883
[TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
11. Adenosine enhances cisplatin sensitivity in human ovarian cancer cells.
Sureechatchaiyan P; Hamacher A; Brockmann N; Stork B; Kassack MU
Purinergic Signal; 2018 Dec; 14(4):395-408. PubMed ID: 30078088
[TBL] [Abstract][Full Text] [Related]
12. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
Kalayda GV; Jansen BA; Wielaard P; Tanke HJ; Reedijk J
J Biol Inorg Chem; 2005 May; 10(3):305-15. PubMed ID: 15824924
[TBL] [Abstract][Full Text] [Related]
13. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
14. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
Zheng L; Li L; Lu Y; Jiang F; Yang XA
Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
[TBL] [Abstract][Full Text] [Related]
15. Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells.
Schneiderman D; Kim JM; Senterman M; Tsang BK
Apoptosis; 1999 Aug; 4(4):271-81. PubMed ID: 14692397
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
Singh M; Chaudhry P; Fabi F; Asselin E
BMC Cancer; 2013 May; 13():233. PubMed ID: 23663432
[TBL] [Abstract][Full Text] [Related]
18. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
20. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
